DexCom, Inc. (DXCM)
| Market Cap | 47.95B |
| Revenue (ttm) | 3.40B |
| Net Income (ttm) | 377.00M |
| Shares Out | 386.37M |
| EPS (ttm) | 0.91 |
| PE Ratio | 136.36 |
| Forward PE | 74.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,301,730 |
| Open | 123.78 |
| Previous Close | 124.16 |
| Day's Range | 123.64 - 124.78 |
| 52-Week Range | 74.75 - 139.55 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 132.94 (+7.13%) |
| Earnings Date | Feb 8, 2024 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into t... [Read more]
Financial Performance
In 2022, DexCom's revenue was $2.91 billion, an increase of 18.84% compared to the previous year's $2.45 billion. Earnings were $341.20 million, an increase of 57.31%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for DXCM stock is "Buy." The 12-month stock price forecast is $132.94, which is an increase of 7.13% from the latest price.
News
3 Medical-Device Stocks Could Click in 2024
Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.
Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. ...
Dexcom G7 is Now the Most Accurate, Smallest, Easy-to-Use CGM Connected to the Tandem t:slim X2 Insulin Pump
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitor...
'Ten-bagger' stocks are the 'holy grail': Strategist
As Wall Street weighs whether markets can sustain November's rally, investors are spotting opportunities. eToro Global Markets Strategist Ben Laidler joined Yahoo Finance Live to analyze high-growth "...
Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitor...
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Piper San...
DexCom CF0: GLP-1s and continuous glucose monitoring are companion therapies
Jereme Sylvain, CFO at DexCom joins Bloomberg Radio to discuss DexCom's earnings and financial outlook. -------- Get more on The Tape Podcast On Apple: http://bit.ly/3YrBfOi On Spotify: http://bit.ly/...
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day
SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) systems for people with diabetes, is teaming up with D...
Earnings-season winners: 20 companies that have grown sales while improving profit margins
Earnings season is a time when investors like to see a “beat and raise” pattern. That is, companies report sales and earnings that surprise the market by coming in ahead of analysts' estimates.
Dexcom stock climbs as worries surrounding weight-loss drugs fades
CNBC's Angelica Peebles joins 'Closing Bell Overtime' to take a closer look at stock movers in the healthcare sector.
Dexcom Stock Soars on Earnings. Ozempic Isn't the Threat It Was Supposed to Be
The maker of continuous glucose monitoring devices said there was no sign weight-loss drugs were hurting demand for its products.
Diabetes stocks jump as obesity-drug recovery comes ahead of schedule, analysts say
Diabetes-device makers' stocks are breaking out of ‘GLP-1 jail' ahead of schedule, analysts say, after months of stock-market punishment based on fears that the popular obesity drugs would clobber the...
Glucose monitor maker DexCom's stock soars after big earnings beat, raised revenue outlook as real-time monitoring awareness grows
Shares of DexCom Inc. DXCM, -3.86% shot up 15.3% to pace the S&P 500's SPX, -1.18% after-hours gainers on Thursday, after of maker of glucose monitoring systems reported third-quarter profit that beat...
Dexcom lifts 2023 revenue view on strong demand for diabetes devices
Medical device maker Dexcom on Thursday raised its annual revenue forecast and beat quarterly estimates on strong demand for its continuous glucose monitoring (CGM) devices, sending its shares more th...
Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #Dexcom--Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program.
The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan
Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same...
Is the Ozempic-Driven DexCom Selloff Overdone?
Plenty of businesses, such as PepsiCo Inc. NYSE: PEP and Walmart Inc. NYSE: WMT, have been under the microscope on fears of potential earnings decreases due to growing use of products like Novo Nordis...
What other industries could weight loss drugs disrupt?
Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
Diabetes-related stocks take hit over weight loss drug craze
This segment originally aired on October 5, 2023 Weight loss drugs, like Novo Nordisk's (NVO) Ozempic, have become popular across healthcare providers in regard to diabetes treatment. Although use is ...
Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its next-gene...
Weight-Loss-Drug Stock Sting May Be Easing for Device Makers
Wall Street says insulin pump maker Insulet and Tandem Diabetes, as well as glucose-monitor maker DexCom, look ready to rise after pressure from Novo Nordisk's Wegovy and Eli Lilly.
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #COMISAIR--Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD.
Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023. Management wi...